Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Xetra  >  Expedeon AG    EXN   DE000A1RFM03


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations
The feature you requested does not exist. However, we suggest the following feature:

Expedeon AG: Expedeon AG announces conversion to registered shares

share with twitter share with LinkedIn share with facebook
share via e-mail
10/04/2019 | 10:05am EST

DGAP-News: Expedeon AG / Key word(s): Miscellaneous
Expedeon AG: Expedeon AG announces conversion to registered shares (news with additional features)

04.10.2019 / 16:00
The issuer is solely responsible for the content of this announcement.

04 October 2019

Expedeon AG announces conversion to registered shares

Heidelberg, Germany and Cambridge, UK, 04 October 2019 - Expedeon AG (Frankfurt: EXNN; ISIN: DE000A2YN801; Prime Standard) today converted its bearer shares into registered shares. The registered shares of Expedeon AG are now under the new ISIN DE000A2YN801 (formerly: DE000A1RFM03) or WKN A2YN80 (formerly: A1RFM0). The stock symbol changes to EXNN (formerly: EXN). The conversion to registered shares is free of charge for shareholders.

The conversion from bearer shares to registered shares was approved at the Annual General Meeting on 9 July 2019. Registered shares require the maintenance of a share register in which the shareholders of Expedeon AG are entered, stating their name, date of birth and address as well as the number of shares they hold. Only shareholders who are entered on the share register are deemed to be shareholders of Expedeon AG and are entitled to attend and vote at Annual General Meetings. Entry on the share register is made by the shareholders' depositary banks. Further steps by the shareholders are not required.

The legal status of the shareholders entered on the share register will not be affected by the conversion to registered shares. Their shareholding in the company remains unchanged. Furthermore, the right of shareholders to sell their shares or to purchase shares is not restricted or impeded.

For further information, please contact:

Expedeon AG
Dr. Heikki Lanckriet
Phone: +44 1223 873 364
Email: heikki.lanckriet@expedeon.com
Investor website: www.investors.expedeon.com

MC Services AG (Investor Relations and International Media Relations)
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 0
Email: expedeon@mc-services.eu

About Expedeon AG: www.expedeon.com
Expedeon is an enabler of exciting advances in medical science and patient care. The Company's core technologies, innovative products and services are used in research laboratories around the world, enabling scientists to push the boundaries of research and product development, and play an integral part in new diagnostic tools being brought to market. With applications spanning the entire workflows in genomics, proteomics and immunology, Expedeon's technologies both accelerate and simplify research and make new and cost-effective processes available to biopharmaceutical and diagnostic organisations alike, thereby underpinning its customers' development and commercialisation objectives. Expedeon's products are sold through a direct sales force and several distribution partners in Europe, the USA and Asia. Expedeon AG has offices in Germany, Spain, UK, USA and Singapore. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: EXN; ISIN: DE000A1RFM03).

### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of Expedeon AG may deviate greatly from the established conclusions or implied predictions contained in such statements. Expedeon does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###

Additional features:

Document: http://n.eqs.com/c/fncls.ssp?u=AYQPWYLEKU
Document title: Registered_Shares

04.10.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language: English
Company: Expedeon AG
Waldhofer Str. 102
69123 Heidelberg
Phone: +49 (0) 6221 3540 125
Fax: +49 (0) 6221 3540 127
E-mail: investors@expedeon.com
Internet: www.expedeon.com
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 885751

End of News DGAP News Service

885751  04.10.2019 


© EQS 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on EXPEDEON AG
11/11EXPEDEON AG : Expedeon AG signs EUR 120 million deal with Abcam for the sale of ..
11/11EXPEDEON AG : Expedeon AG signs EUR 120 million deal with Abcam for the sale of ..
11/08EXPEDEON : Announcement – Margarita Salas
11/07EXPEDEON : reports third quarter 2019 financial results with strongest ever reve..
11/07EXPEDEON AG : Expedeon AG reports third quarter 2019 financial results with stro..
11/05EXPEDEON : 05/11/2019
11/05EXPEDEON AG : Preliminary announcement of the publication of quarterly reports a..
10/31EXPEDEON AG : Release according to Article 41 of the WpHG [the German Securities..
10/29EXPEDEON AG : Expedeon AG raises adjusted EBITDA guidance for 2019
10/29EXPEDEON AG : Expedeon AG raises adjusted EBITDA guidance for 2019
More news
Financials (EUR)
Sales 2019 16,0 M
EBIT 2019 -0,81 M
Net income 2019 -1,24 M
Debt 2019 3,36 M
Yield 2019 -
P/E ratio 2019 -84,3x
P/E ratio 2020 127x
EV / Sales2019 4,35x
EV / Sales2020 3,35x
Capitalization 66,2 M
Duration : Period :
Expedeon AG Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Mean consensus BUY
Number of Analysts 2
Average target price 2,70  €
Last Close Price 1,27  €
Spread / Highest target 153%
Spread / Average Target 113%
Spread / Lowest Target 73,9%
EPS Revisions
Heikki Lanckriet Chief Executive Officer & Chief Scientific Officer
Joseph M. Fernández Chairman-Supervisory Board
David Roth Chief Financial Officer
Pilar de la Huerta Martinez Member-Supervisory Board
Timothy Paul McCarthy Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP35.41%25 888
CELLTRION, INC.--.--%21 663